

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 March 2016 (10.03.2016)

(10) International Publication Number
WO 2016/037005 A1

(51) International Patent Classification:
C07D 253/06 (2006.01)

(21) International Application Number:
PCT/US2015/048429

(22) International Filing Date:
3 September 2015 (03.09.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/046,842 5 September 2014 (05.09.2014) US

(71) Applicant: **QUANTICEL PHARMACEUTICALS, INC.** [US/US]; 9393 Towne Centre Drive, Suite 110, San Diego, CA 92121 (US).

(72) Inventors: **CHEN, Young, K.**; 746 Santa Barbara Drive, San Marcos, CA 92078 (US). **KANOUNI, Toufike**; 9253 Regents Road, Unit A103, La Jolla, CA 92037 (US). **STAFFORD, Jeffrey, Alan**; 12752 Sandy Crest Court, San Diego, CA 92130 (US). **VEAL, James, Marvin**; 8916 Weaver Crossing Road, Apex, NC 27502 (US).

(74) Agent: **CLARK, David, L.**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1

(57) Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.



WO 2016/037005 A1

ADVANCE E-MAIL

From the INTERNATIONAL BUREAU

PCTNOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

SUNG, Lawrence, M.
Wiley Rein LLP
Patent Administration
1776 K Street, NW
Washington, DC 20006
ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (day/month/year) 27 February 2017 (27.02.2017)	
Applicant's or agent's file reference 873860017PCT	IMPORTANT NOTIFICATION
International application No. PCT/US2015/048429	International filing date (day/month/year) 03 September 2015 (03.09.2015)

1. The following indications appeared on record concerning: ☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative		
Name and Address QUANTICEL PHARMACEUTICALS, INC. 9393 Towne Centre Drive Suite 110 San Diego, CA 92121 United States of America	State of Nationality US	State of Residence US
	Telephone No.	
	Facsimile No.	
	E-mail address	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning: ☒ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence		
Name and Address CELGENE QUANTICEL RESEARCH, INC. 9393 Towne Centre Drive Suite 110 San Diego, CA 92121 United States of America	State of Nationality US	State of Residence US
	Telephone No.	
	Facsimile No.	
	E-mail address ☐ Notifications by e-mail authorized	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to: ☒ the receiving Office ☐ the International Preliminary Examining Authority ☐ the International Searching Authority ☒ the designated Offices concerned ☐ the Authority(ies) specified for supplementary search ☐ the elected Offices concerned ☐ other:		

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Beard Nathalie e-mail pct.team6@wipo.int Telephone No. +41 22 338 74 06
Facsimile No. +41 22 338 89 70	